Millions of Women Use These Contraceptives. Europe Just Flagged a Brain Tumor Link.
Europe's drug safety watchdog flagged a small brain tumor risk linked to widely used progestin contraceptives containing desogestrel and etonogestrel. The finding could affect prescribing for millions of women and force label changes on products like Nexplanon.
Imagine you've been taking the same birth control pill for years. It works, it's easy, you barely think about it. Now a European safety committee says it might, in very rare cases, be linked to a type of brain tumor.
That's the situation facing millions of women who use contraceptives containing desogestrel or etonogestrel, two closely related progestins found in popular pills, implants, and vaginal rings. The European Medicines Agency's safety watchdog, the PRAC, has flagged a small increased risk of meningioma (a usually benign tumor growing on the membranes surrounding the brain) with prolonged use of these contraceptives. The finding is based on a massive Danish registry study tracking women from 2000 to 2024, and it could eventually trigger label changes for some of the most widely prescribed birth control products on the planet.
Before anyone flushes their pills down the toilet: the risk is genuinely small. But "small" multiplied by "millions of users" is how safety signals become front-page news.
What the Data Actually Shows
The Danish study found that women using progestin-containing contraceptives had a slightly higher rate of meningioma compared to non-users. The signal was strongest in women who used these products continuously for five years or more, and it essentially disappeared in women who had stopped using them for more than five years.
A separate French case-control study zeroed in on desogestrel specifically. Women taking the 75 µg desogestrel-only pill for more than five years had roughly 1.3 to 1.7 times the odds of developing a meningioma requiring treatment. Push that out to seven-plus years, and the odds ratio climbed to about 2.1. For context, that's still a rare event: the French drug agency estimated roughly one meningioma requiring surgery per 17,000 women exposed for more than five years.
Short-term users? Their risk looked no different from women who never touched the stuff.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Etonogestrel is the active metabolite of desogestrel. Think of it this way: when you swallow desogestrel, your body converts it into etonogestrel. They're basically the same molecule wearing different outfits.
That's why the etonogestrel implant (sold as Nexplanon, used by over 20 million women worldwide) and desogestrel-containing combined pills got swept into the same safety discussion, even though neither product was directly studied in the key French dataset. The French drug regulator, ANSM, called the extrapolation "highly probable" and extended its precautionary advice accordingly.
No robust, large-scale study has yet produced a standalone risk estimate for etonogestrel implants. That's an important caveat: the concern is biologically logical but epidemiologically unproven for that specific product.
This Isn't Europe's First Rodeo
The PRAC has been playing whack-a-mole with progestin-meningioma signals for nearly two decades. The timeline reads like a slow-rolling detective story.
It started around 2008 with case reports linking high-dose cyproterone acetate to brain tumors. By 2020, the EMA had confirmed a dose-dependent meningioma risk and slapped on prescribing restrictions. Then came nomegestrol and chlormadinone in 2022, followed by high-dose medroxyprogesterone acetate (the injectable known as Depo-Provera at high doses) in 2024. Each time, the playbook was similar: contraindicate the drug in women with current or past meningioma, update labels, and tell doctors to use the lowest dose for the shortest time.
Desogestrel and etonogestrel are now next in line. The pattern suggests formal EU-wide measures could follow, though nothing binding has been adopted yet.
Meanwhile, the FDA has been notably quiet. Some of the implicated drugs (cyproterone, nomegestrol, chlormadinone) aren't even sold in the United States, which partly explains the silence.
One Progestin Dodged the Bullet
Here's an interesting wrinkle: levonorgestrel, another popular progestin found in many IUDs and pills, showed no increased meningioma risk in the French study, regardless of how long women used it. That distinction matters. If you're a clinician weighing options for a patient over 45 who needs long-term contraception, levonorgestrel-based products just got a little more attractive by comparison.
What This Means for Organon (and Your Portfolio)
The company most exposed here is Organon (ticker: OGN), which owns Nexplanon after being spun out of Merck. Organon has been having a complicated year already; the FDA recently approved extending Nexplanon's labeled use from three to five years (good news) while simultaneously requiring a new REMS program with mandatory provider certification (complicated news).
The market's reaction to the regulatory updates has been muted. Investors seem to view the five-year extension as a long-term positive that's offset by near-term friction from the REMS rollout. A meningioma-related label change from the EMA could add another layer of uncertainty, though the "very rare" risk classification makes a dramatic market reaction unlikely.
Merck's exposure is minimal since the Organon spinoff.
The Bottom Line for Patients and Doctors
No regulator is telling women to stop taking their birth control. The Danish and French authorities were explicit about that. The benefits of effective contraception far outweigh a very rare tumor risk for the vast majority of users.
But the practical advice is shifting. Experts say clinicians should now:
Review contraceptive choices in women over 45 or those approaching five-plus years of continuous desogestrel/etonogestrel use.
Avoid these products in women with a current or past meningioma.
Stop the contraceptive and refer to a neurosurgeon if a meningioma is diagnosed.
Watch for symptoms like progressive headaches, vision changes, hearing loss, or seizures in long-term users.
Routine brain scans are not recommended for women on desogestrel, which tells you something about how low the absolute risk really is.
The PRAC is still evaluating the data, and formal EU-wide label changes haven't landed yet. But given the agency's track record with other progestins, the direction of travel seems clear. The real question isn't whether labels will change; it's how quickly prescribers adapt their habits before the paperwork catches up.
Deals & M&A4 min read
Bayer Just Sold a Piece of Its Birth Control Empire (But Kept the Keys)
Bayer just pulled €3 billion from Apollo without giving up control of its blockbuster IUD franchise. It's a clever financial move, but the real story is why the German pharma giant needed the cash so badly in the first place.
